Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Migraine is a debilitating neurological condition affecting millions.
• Subcutaneous sumatriptan is an established migraine treatment.
• Novel drug delivery systems aim to improve patient experience and adherence.

Purpose of the Study:

• To evaluate the efficacy and tolerability of subcutaneous sumatriptan (6 mg) using the IMITREX STATdose System.
• To compare the novel device against placebo in a randomized, double-masked, multicenter trial.
• To assess the safety profile of this administration method.

Main Methods:

• Two randomized, double-masked, parallel-group, placebo-controlled studies.
• 158 adults with International Headache Society-diagnosed migraine received either SC sumatriptan (6 mg) or placebo via the IMITREX STATdose System.
• Efficacy endpoints included headache relief, clinical disability, nausea, phonophobia, and photophobia at 120 minutes post-dose.

Main Results:

• Significant headache relief was observed in 73-79% of sumatriptan recipients versus 28-37% of placebo recipients at 120 minutes.
• Clinical disability scores improved significantly, with 75-85% of sumatriptan users being normal or mildly impaired compared to 30-42% in the placebo group.
• Similar efficacy was noted for associated migraine symptoms; no serious adverse events or clinically relevant lab abnormalities were reported.

Conclusions:

• Subcutaneous sumatriptan (6 mg) administered via the IMITREX STATdose System is an effective migraine treatment.
• The device provides a safe and tolerable alternative to conventional syringe administration.
• This delivery system offers comparable efficacy and tolerability to traditional SC sumatriptan.